Aclarion Announces Agreement with Weill Cornell Medicine
MWN-AI** Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company focused on chronic low back pain solutions, has announced a new commercial agreement with Weill Cornell Medicine. This partnership will introduce Aclarion's innovative Nociscan technology to the multidisciplinary spine team at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, led by Dr. Jaspal Ricky Singh, a renowned expert in spinal health.
Nociscan is a SaaS platform designed to noninvasively assist physicians in identifying painful versus non-painful lumbar discs by quantifying chemical biomarkers linked to disc pain. The collaboration will focus on a trial aimed at evaluating the effectiveness of bone marrow aspirate stem cell concentrate (BMAC) in treating osteoarthritis and degenerative disc disease. The prospective study will also involve spine patients, selected based on clinical evaluations by Dr. Singh, who may benefit from Nociscan technology.
Dr. Singh emphasized the team's commitment to a comprehensive and multidisciplinary approach to treating spinal disorders, integrating various therapies and interventions to optimize patient outcomes. The goal of the study is to analyze whether variations in the dosing and quantity of BMAC can correlate with improved functional outcomes and reductions in pain for patients with degenerative spine conditions.
Chronic low back pain (cLBP) affects an estimated 266 million people globally, making the insights provided by Aclarion's Nociscan particularly valuable for advancing treatment methodologies. Through advanced magnetic resonance spectroscopy and proprietary algorithms, Nociscan aims to enhance diagnostic clarity and treatment strategies, positioning Aclarion at the forefront of spinal healthcare innovation. For further details on the partnership and Nociscan, interested parties can visit Aclarion’s website.
MWN-AI** Analysis
Aclarion, Inc. (NASDAQ: ACON) has recently made headlines with its commercial agreement with Weill Cornell Medicine, a move that emphasizes its innovative approach in addressing chronic low back pain through its proprietary Nociscan technology. This agreement will allow Aclarion to integrate its SaaS platform into a renowned clinical setting, potentially enhancing market credibility and driving adoption.
Chronic low back pain (cLBP) impacts approximately 266 million individuals globally, underscoring a significant clinical need that Aclarion targets with Nociscan. The technology employs Magnetic Resonance Spectroscopy (MRS) combined with AI algorithms to accurately identify painful lumbar discs, facilitating targeted treatment options. This specificity could lead to higher patient satisfaction, improved outcomes, and reduced healthcare costs, thus appealing strongly to healthcare providers.
In the current market context, the emphasis on data-driven healthcare solutions positions Aclarion favorably. Collaborations with established institutions like Weill Cornell can enhance visibility and trust in its offerings. Investors should closely monitor patient enrollment in the ongoing clinical trials and results resulting from this partnership, as successful outcomes could propel the company's stock value.
However, it’s important to recognize potential risks. The healthcare technology landscape is competitive, and the regulatory environment can pose challenges that may affect timelines and market penetration. The company's reliance on forward-looking statements necessitates cautious optimism; investors should be vigilant regarding Aclarion's ongoing disclosures and updates.
In conclusion, Aclarion's strategic partnership with Weill Cornell Medicine signifies a proactive approach to expand its market presence. For investors, this may provide a valuable opportunity, contingent upon closely watching clinical developments and market response. Diversification in their investment portfolio and consistent risk assessment will be key to navigating the evolving landscape of healthcare technology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine.
The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team led by triple-board certified physician and Principal Investigator, Jaspal Ricky Singh, MD, who has earned a national reputation for innovation and excellence. The trial is entitled “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease,” conducted under IRB Protocol No. 22-06024915.
The purpose of this initial study is to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate (BMAC) used for the treatment of osteoarthritis and/or Degenerative Disc Disease in the spine has an effect on patient-reported functional outcomes and pain. A subset of spine patients, selected per Dr. Singh’s clinical evaluation, will also be eligible for Nociscan.
“Our team takes a comprehensive approach to the treatment of spinal disorders. Our multidisciplinary approach to treat pain includes physical therapy and various interventional techniques,” said Jaspal Ricky Singh, MD, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine and Rehabilitation Medicine Specialist at Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. “Our pioneering research into discogenic low back pain and cBMA (concentrated bone marrow aspirate) is an ideal opportunity to utilize the insights provided by Nociscan.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. 1 Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan can provide critical insights into the location of a patient’s low back pain and improves pain and function when all Nociscan-positive discs are treated.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
References:
- Ravindra VM, Global Spine Journal (2018) 8(8): 784-794, AO Spine.
FAQ**
How does Aclarion Inc. plan to leverage its technology in Nociscan to enhance the commercial potential of Aclarion Inc. Warrant ACONW in the competitive healthcare market?
What specific outcomes does Aclarion anticipate from the trial at Weill Cornell Medicine that could impact the market perception of Aclarion Inc. Warrant ACONW?
In what ways might the partnership with Weill Cornell Medicine influence the financial viability and growth trajectory of Aclarion Inc. Warrant ACONW?
How does Aclarion’s research into biomarkers and AI algorithms position the company to attract investors, particularly those interested in Aclarion Inc. Warrant ACONW?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. (NASDAQ: ACON).
NASDAQ: ACON
ACON Trading
-4.06% G/L:
$3.425 Last:
49,457 Volume:
$3.49 Open:
